Influence of intense multidisciplinary follow-up and orlistat on weight reduction in a primary care setting

BMC Family Practice

Volumn 6, Issue , 2005, Pages

  Feigenbaum, Amiel ^a   Pasternak, Shmuel ^b   Zusk, Efrat ^a   Sarid, Miri ^c   Vinker, Shlomo ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b Primary Care Clinic   (Israel)

^c Sarid Institute   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; ANTIOBESITY AGENT; LACTONE; LIPID; TRIACYLGLYCEROL LIPASE;

ADULT; AGED; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DEFECATION DISORDER; DIET; DIETITIAN; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLATULENCE; FOLLOW UP; GASTROINTESTINAL DISEASE; GENERAL PRACTITIONER; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIMARY MEDICAL CARE; SIDE EFFECT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; BLOOD; BODY MASS; CLINICAL TRIAL; DIET THERAPY; DRUG EFFECTS; GENERAL PRACTICE; HEALTH SERVICES RESEARCH; ISRAEL; LOW CALORY DIET; MIDDLE AGED; PATIENT CARE; PRIMARY HEALTH CARE; STANDARDS; TREATMENT OUTCOME;

ADULT; ANTI-OBESITY AGENTS; BODY MASS INDEX; CONTINUITY OF PATIENT CARE; DIET, REDUCING; FAMILY PRACTICE; FEMALE; HEALTH SERVICES RESEARCH; HUMANS; ISRAEL; LACTONES; LIPASE; LIPIDS; MALE; MIDDLE AGED; OBESITY; PATIENT CARE TEAM; PRIMARY HEALTH CARE; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 14544284111     PISSN: 14712296     EISSN: 14712296     Source Type: Journal    
DOI: 10.1186/1471-2296-6-5     Document Type: Article

References (30)

1. Foreyt J, Goodrick K: The ultimate triumph of obesity. Lancet 1995, 346:34-35.
2. Bray GA: Contemporary Diagnosis and Management of Obesity City: Handbooks in Health Care Company; 1998.
3. Hill JO, Wyatt H: Outpatient management of obesity: a primary care perspective. Obes Res 2002, 2:124-130.
4. US Department of Health and Human Services: The Surgeon General's Call to Action to Prevent and Decrease Overweight and Obesity Rockville,Md; 2001.
5. Yanovski SZ, Yanovski JA: Obesity. N Engl J Med 2002, 346:591-602.
6. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS: Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003, 289:76-79.
7. Nizan-Kaluski D: The Israel Survey of Obesity Nutrition Department, Israel Ministry of Health; 2000. (in Hebrew)
8. Goldstein DJ: Beneficial effects of modest weight loss. Int J Obese 1992, 16:397-415.
9. Thompson D, Edelsberg J, Colditz GA, Bird AP, Oster G: Lifetime health and economic consequences of obesity. Arch Intern Med 1999, 159:2177-2183.
10. Weisberg SP: Societal change to prevent obesity - editor's note. JAMA 2002, 288:2176.
11. Manson JE, Willett WC, Stampfer MJ, Colditz GA, Hunter DJ, Hankinson SE, Hennekens CH, Speizer FE: Body weight and mortality among women. N Engl J Med 1995, 333:677-685.
12. Blumenthal SJ, Hendi JM, Marsillo L: A Public Health Approach to Decreasing Obesity. JAMA 2002, 288(17):2178.
13. Bray GA: Obesity: a time bomb to defused. Lancet 1998,352:160-161.
14. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW: Body mass index and mortality in a prospective cohort of US adults. NEJM 1999, 341:1097-1105.
15. Wing R, Venditti E, Jakicic J, Polley B, Lang W: Lifestyle intervention in overweight individuals with a family history of diabetes. Diabetes Care 1998, 21:350-360.
16. Grizzard T: Undertreatment of obesity. JAMA 2002, 288:2177.
17. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR: Orlistat in long-term treatment of obesity in primary care settings. Arch Fam Med 2000, 9:160-167.
18. Williamson DF, Pamuk E, Thus M, Flanders D, Byers T, Heath C: Prospective study of international weight loss and mortality in never smoking US white women aged 40-64 years. Am J Epidemiol 1995, 141:1128-1141.
19. Logue EE, Smucker WD: Obesity management in primary care: changing the status quo. J Fam Pract 2001, 50:520.
20. Bowerman S, Bellman M, Saltsman P, Garvey D, Pimstone K, Skootsky S, Wang HJ, Elashoff R, Heber D: Implementation of primary care physicians network obesity management program. Obes Res 2001, 4:321-325.
21. National Institutes of Health: Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - the evidence report. Obes Res 1998, 6:S51-S209.
22. Israel Medical Association: Clinical Guidelines on the Prevention and Treatment of Obesity The Scientific Council; 2003. (in Hebrew)
23. Noel PH, Pugh JA: Management of overweight and obese adults. BMJ 2002, 325:757-761.
24. Nawaz H, Katz DL: American College of Preventive Medicine Practice Policy statement. Weight management counseling of overweight adults. Am J Prev Med 2001, 21:73-78.
25. Hill JO, Hauptman J, Anderson JW, Fujioka K, O'Neil PM, Smith DK, Zavoral JH, Aronne LJ: Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a one year study. Am J Clin Nutr 1999, 69:1108-1116.
26. Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, Krempf M: Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998, 352:161-167.
27. Zavoral JH: Treatment with orlistat reduces cardiovascular risk in obese patients. J Hypertension 1998, 16:2013-2017.
28. Beermann B, Melander H, Sawe J, Ulleryd C, Dahlqvist R: Incorrect use and limited weight reduction of orlistat (Xenical) in clinical practice. A cohort study. Eur J Clin Pharmacol 2001,57:309-11.
29. Linne Y, Rooth P, Rossner S: Success rate of Orlistat in primarycare practice is limited by failure to follow prescribing recommendations: the referral letter content vs clinical reality. Int J Obes Relat Metab Disord 2003, 27:1434-5.
30. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR: Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000, 9:160-7.